• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Etrolizumab for ulcerative colitis: the new kid on the block?
【24h】

Etrolizumab for ulcerative colitis: the new kid on the block?

机译：Etrolizumab治疗溃疡性结肠炎：新来的孩子是否受阻？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown etiology. Currently approved therapies include prednisone, TNF antagonists and anti-metabolites which often are ineffective and have frequent adverse effects. Consequently, UC patients are always at risk for developing serious complications that affect their quality of life. Therefore, new treatment options are required. Areas covered: This article discusses etrolizumab, its mechanism and the potential role it can have in the future of treating UC. Etrolizumab is a humanized monoclonal antibody that selectively blocks lymphocyte trafficking and retention in the gut. The safety and efficacy data was reviewed from all randomized placebo-controlled trials which evaluated etrolizumab for the treatment of UC. Expert opinion: Etrolizumab is an effective and well-tolerated drug for the treatment of UC. It appears to be a promising molecule that can benefit UC patients.
机译：简介：溃疡性结肠炎（UC）是一种病因不明的慢性炎症性肠病。目前批准的疗法包括泼尼松，TNF拮抗剂和抗代谢药物，这些药物通常无效且频繁出现不良反应。因此，UC患者总是有发生严重并发症的风险，这些并发症会影响他们的生活质量。因此，需要新的治疗选择。涵盖的领域：本文讨论了埃特罗珠单抗，其机制以及它在未来治疗UC中可能具有的潜在作用。 Etrolizumab是一种人源化单克隆抗体，可选择性地阻断淋巴细胞的运输和保留在肠道中。从评估埃特罗珠单抗治疗UC的所有随机安慰剂对照试验中回顾了安全性和有效性数据。专家意见：Etrolizumab是治疗UC的有效且耐受性良好的药物。它似乎是可以使UC患者受益的有希望的分子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号